Top 2022 stories highlighting COVID-19 impact on asthma, allergy
Click Here to Manage Email Alerts
Nearly 3 years into the pandemic, COVID-19 continues to dominate headlines and research labs as scientists explore therapies that mitigate the impact of the virus, particularly among patients with asthma and allergy.
Here are the year’s 10 most popular stories about these developments.
Intranasal corticosteroids mitigate loss of smell in chronic rhinosinusitis with COVID-19
Doctors should consider intranasal corticosteroids for patients with chronic rhinosinusitis who also have COVID-19 to minimize loss of olfactory function, according to a study published in Allergy and Asthma Proceedings. Read more.
Food allergy associated with lower SARS-CoV-2 infection risk
People with food allergies showed lower risk for SARS-CoV-2 infection, whereas those with current asthma and those with obesity had a higher risk, according to a study published in The Journal of Allergy and Clinical Immunology. Read more.
Q&A: Does asthma mitigate the risk for COVID-19?
Monica Kraft, MD, discusses what is known about the link between asthma and other respiratory diseases as well as what researchers hope to discover about the link between asthma and COVID-19 in this exclusive Q&A. Read more.
Split dosing of COVID-19 vaccines provides antibody responses
Patients with concerns about vaccination reactions can receive a smaller dose, be observed for 30 minutes, and receive the remainder of the dose without any loss in efficacy, Jill A. Poole, MD, FAAAAI, FACAAI, told Healio. Read more.
Omicron’s more mild nature may ease challenges for patients with immunodeficiencies
Omicron may be more transmissible, but it also has been associated with lower rates of acute respiratory distress syndrome, hospitalization and death, researchers reported in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Epstein-Barr virus reactivation may contribute to long COVID fatigue
Epstein-Barr virus replication may be a cofactor in a subgroup of patients who develop long COVID fatigue, although other potential contributing factors need to be evaluated as well, according to a letter published in Allergy. Read more.
Registry data reveal symptoms, outcomes of anaphylaxis from COVID-19 vaccination
Anaphylaxis accounted for 15% of the adverse reports from clinicians after mRNA vaccinations for COVID-19, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Read more.
Dupilumab for atopic dermatitis linked to lower antibody levels after COVID-19 infection
Although many patients may be concerned that immune-modifying treatments may make them more vulnerable to COVID-19, dupilumab may reduce symptom severity, Benjamin Ungar, MD, told Healio. Read more.
Following reactions to first COVID-19 vaccine, children can safely receive second dose
The second dose of the Pfizer-BioNTech vaccine can be administered safely in children with a history of immediate and potentially allergic reactions to the first dose, as well as in children with a history of polyethylene glycol or polysorbate allergy, Joel P. Brooks, DO, MPH, told Healio. Read more.
Patients tolerate mRNA COVID-19 vaccines despite hypersensitivity to taxanes
Patients with previous hypersensitivity reactions to paclitaxel with the excipient Cremophor EL or docetaxel with the excipient polysorbate 80 tolerated COVID-19 vaccines safely, researchers reported in The Journal of Allergy and Clinical Immunology: In Practice. Read more.